Search Medical Condition
Please enter condition
Please choose location

Jeju-si, Korea, Republic of Clinical Trials

A listing of Jeju-si, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (15) clinical trials

Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled extension study to characterising the long term safety and tolerability of of an intravenous treatment regimen of anifrolumab versus placebo in subjects with moderately to severely active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or D3461C00005) through ...

Phase

0.0 miles

Learn More »

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

This study is designed as a phase III, prospective, randomized, open-label, multicenter clinical trial comparing GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in treating locally advanced and metastatic pancreatic cancer patients. Patients will be treated until disease progression and will be subject to follow-up until death. Patients will be randomized ...

Phase

0.0 miles

Learn More »

Mode of Dialysis Therapy and Outcomes in End Stage Renal Disease (ESRD)

The number of ESRD patients is growing at a much faster rate than the total population, with almost 1,000 (941.7) ESRD patients per one million as of 2006. The ESRD prevalence in Korea is ranked as high as 10th globally. The most common underlying diseases of ESRD in Korea include ...

Phase N/A

0.0 miles

Learn More »

Mucopolysaccharidosis I (MPS I) Registry

The MPS I Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: - In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com - In Europe - +31-35-699-1232, europe@mpsiregistry.com - In Latin America - +617-591-5500, help@mpsiregistry.com - In North America - +617-591-5500, ...

Phase N/A

0.0 miles

Learn More »

Fabry Disease Registry

The Fabry Registry is an international program; in addition to the central contact information provided under the "Location" heading, patients may contact: - In Asia-Pacific - Vivian Liu, +65-6431-2548, Vivian.liu@genzyme.com - In Europe - +31-35-699-1232, europe@FabryRegistry.com - In Latin America - +617-591-5500, help@FabryRegistry.com - In North America - +617-591-5500, help@FabryRegistry.com

Phase N/A

0.0 miles

Learn More »

Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".

The objective of this surveillance is to identify problems and questions on Cholib® and on the following matters under the condition that the investigational product is in use. 1. Serious adverse event and adverse drug reaction profile - Death or a life-threatening condition - Hospitalization or prolonged hospitalization - Persistent ...

Phase N/A

2.03 miles

Learn More »

Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled

A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

Phase

2.03 miles

Learn More »